GeneLink, Inc.
GNLKQ
$0.00
$0.000.00%
OTC PK
| 09/30/2013 | 06/30/2013 | 03/31/2013 | 12/31/2012 | 09/30/2012 | |
|---|---|---|---|---|---|
| Revenue | -30.68% | 18.03% | -48.18% | -53.22% | -60.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.68% | 18.03% | -48.18% | -53.22% | -60.26% |
| Cost of Revenue | -56.84% | -19.46% | -9.08% | 29.96% | 17.43% |
| Gross Profit | 180.82% | 123.27% | -78.69% | -103.16% | -114.21% |
| SG&A Expenses | -12.19% | -37.69% | -64.38% | -60.55% | -50.70% |
| Depreciation & Amortization | 101.56% | -40.27% | -39.92% | -45.12% | -79.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.81% | -33.30% | -51.46% | -43.89% | -33.55% |
| Operating Income | 32.37% | 68.62% | 54.67% | 37.88% | 2.23% |
| Income Before Tax | 44.65% | 66.23% | -234.72% | 29.66% | 0.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.65% | 66.23% | -234.72% | 29.66% | 0.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.65% | 66.23% | -234.72% | 29.66% | 0.37% |
| EBIT | 32.37% | 68.62% | 54.67% | 37.88% | 2.23% |
| EBITDA | 32.79% | 70.22% | 56.43% | 38.95% | 1.26% |
| EPS Basic | 57.45% | 72.34% | -180.00% | 42.03% | 4.08% |
| Normalized Basic EPS | 44.83% | 69.23% | 57.69% | 46.51% | 6.45% |
| EPS Diluted | 57.45% | 72.34% | -180.00% | 42.03% | 4.08% |
| Normalized Diluted EPS | 44.83% | 69.23% | 57.69% | 46.51% | 6.45% |
| Average Basic Shares Outstanding | 26.78% | 27.04% | 23.62% | 20.42% | 4.20% |
| Average Diluted Shares Outstanding | 26.78% | 27.04% | 23.62% | 20.42% | 4.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |